Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: A step toward the truth in the absence of a gold standard

Journal of Hepatology

Volumn 56, Issue 3, 2012, Pages 541-548

  Poynard, Thierry ^a   De Ledinghen, Victor ^b   Zarski, Jean Pierre ^c   Stanciu, Carol ^d   Munteanu, Mona ^e   Vergniol, Julien ^b   France, Julie ^f   Trifan, Anca ^d   Le Naour, Gilles ^a   Vaillant, Jean Christophe ^a   Ratziu, Vlad ^a   Charlotte, Frederic ^b  

^a SORBONNE UNIVERSITÉ   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c Clinique Universitaire d'Hépato Gastroentérologie   (France)

^d Gastroenterology and hepatology institute   (Romania)

^e Biopredictive   (France)

^f GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Accuracy; FibroScan; FibroSure; FibroTest; Hepatitis C; Latent class; Liver biopsy; Methods without gold standard; Non invasive biomarker; Transaminases

Indexed keywords

ALANINE AMINOTRANSFERASE;

ACCURACY; ADULT; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DIAGNOSTIC KIT; DIAGNOSTIC TEST ACCURACY STUDY; FALSE POSITIVE RESULT; FEMALE; GOLD STANDARD; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RIGIDITY; SENSITIVITY AND SPECIFICITY; STAGING;

ALANINE TRANSAMINASE; BIOPSY; DATABASES, FACTUAL; ELASTICITY IMAGING TECHNIQUES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84857360103     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2011.08.007     Document Type: Article

References (36)

1. A.W. Rutjes, J.B. Reitsma, A. Coomarasamy, K.S. Khan, and P.M. Bossuyt Evaluation of diagnostic tests when there is no gold standard. A review of methods Health Technol Assess 11 2007 1 51
2. L. Castera, and M. Pinzani Non-invasive assessment of liver fibrosis: are we ready? Lancet 375 2010 1419 1420
3. T. Poynard First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy J Hepatol 54 2011 586 587
4. P. Halfon, M. Munteanu, and T. Poynard FibroTest-ActiTest as a non-invasive marker of liver fibrosis Gastroenterol Clin Biol 32 2008 22 38
5. M. Friedrich-Rust, M.F. Ong, S. Martens, C. Sarrazin, J. Bojunga, and S. Zeuzem Performance of transient elastography for the staging of liver fibrosis: a meta-analysis Gastroenterology 134 2008 960 974
6. L. Castera, J. Denis, G. Babany, and F. Roudot-Thoraval Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines? J Hepatol 46 2007 528 529
7. P. Bedossa, D. Dargre, and V. Paradis Sampling variability of liver fibrosis in chronic hepatitis C Hepatology 38 2003 1449 1457
8. T. Poynard, P. Ingiliz, L. Elkrief, M. Munteanu, P. Lebray, and R. Morra Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers PLoS One 3 2008 e3857
9. L. Castéra, J. Foucher, P.H. Bernard, F. Carvalho, D. Allaix, and W. Merrouche Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations Hepatology 51 2010 828 835
10. Zarski, N. Sturm, J. Guechot, A. Paris, E.S. Zafrani, and T. Asselah Comparison of 10 blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study J Hepatol 56 2012 55 62
11. I. Sporea, R. Sirli, A. Deleanu, A. Tudora, A. Popescu, and M. Curescu Liver stiffness measurements in patients with HBV vs. HCV chronic hepatitis: a comparative study World J Gastroenterol 16 2010 4832 4837
12. T. Poynard, P. Lebray, P. Ingiliz, A. Varaut, B. Varsat, and Y. Ngo Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest) BMC Gastroenterol 10 2010 40
13. T. Poynard, G. Lenaour, F. Charlotte, M. Munteanu, J.C. Vaillant, and Y. Ngo Comparison of Fibrotest-Fibrosure and liver stiffness measurement, using fibrosis area and large surgical samples Hepatology 52 2010 282A [abstract]
14. A. Kettaneh, P. Marcellin, C. Douvin, R. Poupon, M. Ziol, and M. Beaugrand Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients J Hepatol 46 2007 628 634
15. D. Roulot, S. Czernichow, H. Le Clésiau, J.L. Costes, A.C. Vergnaud, and M. Beaugrand Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome J Hepatol 48 2008 606 613
16. P. Bedossa, and T. Poynard An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group Hepatology 24 1996 289 293
17. Y. Qu, M. Tan, and M.H. Kutner Random effects models in latent class analysis for evaluating accuracy of diagnostic tests Biometrics 52 1996 797 810
18. A. Hadgu, and Y. Qu A biomedical application of latent class models with random effects Appl Stat 47 1998 603 616
19. Vermunt JK, Magidson J. Technical guide to latent gold 4.5. Belmont, Massachusetts, USA: Statistical Innovations Inc.; 2007.
20. X. Zhou, N. Obuchowski, and D. McClish Statistical methods in diagnostic medicine 2002 John Wiley and Sons
21. J. Lambert, P. Halfon, G. Penaranda, P. Bedossa, P. Cacoub, and F. Carrat How to measure the diagnostic accuracy of noninvasive liver fibrosis indices: the area under the ROC curve revisited Clin Chem 54 2008 1372 1378
22. J.L. Hintze NCSS 2007 user guide. Number cruncher statistical systems software 2007 NCSS Kaysville, Utah
23. S.H. Mehta, B. Lau, N.H. Afdhal, and D.L. Thomas Exceeding the limits of liver histology markers J Hepatol 50 2009 36 41
24. M.C. Rousselet, S. Michalak, F. Dupré, A. Croué, P. Bedossa, and J.P. Saint-André Hepatitis network 49. Sources of variability in histological scoring of chronic viral hepatitis Hepatology 41 2005 257 264
25. T. Poynard, P. Halfon, L. Castera, F. Charlotte, B.L. Bail, and M. Munteanu Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation Aliment Pharmacol Ther 25 2007 733 739
26. T. Poynard, M. Munteanu, O. Deckmyn, Y. Ngo, F. Drane, and D. Messous Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age BMC Gastroenterol 11 2011 39
27. B. Coco, F. Oliveri, A.M. Maina, P. Ciccorossi, R. Sacco, and P. Colombatto Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases J Viral Hepat 14 2007 360 369
28. T. Poynard, Y. Ngo, M. Munteanu, D. Thabut, J. Massard, and J. Moussalli Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies Antivir Ther 15 2010 617 631
29. T. Poynard, M. Munteanu, Y. Ngo, L. Castera, P. Halfon, and V. Ratziu ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure Gastroenterol Clin Biol 34 2010 388 396
30. T. Poynard, V. Ratziu, S. Naveau, D. Thabut, F. Charlotte, and D. Messous The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis Comp Hepatol 4 2005 10
31. T. Poynard, M. Munteanu, M. Colombo, J. Bruix, E. Schiff, and R. Terg FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC(3) program J Hepatol 54 2011 227 235
32. Y. Ngo, M. Munteanu, D. Messous, F. Charlotte, F. Imbert-Bismut, and D. Thabut A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C Clin Chem 52 2006 1887 1896
33. J. Vergniol, J. Foucher, E. Terrebonne, P.H. Bernard, B. Le Bail, and W. Merrouche Non-invasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C Gastroenterology 40 2011 1970 1979
34. Y. Ngo, Y. Benhamou, V. Thibault, P. Ingiliz, M. Munteanu, and P. Lebray An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load PLoS One 2 2008 e2573
35. S. Naveau, G. Gaudé, A. Asnacios, H. Agostini, A. Abella, and N. Barri-Ova Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease Hepatology 49 2009 97 105
36. La Haute Autorité de Santé (HAS) in France - The HAS recommendations for the management of the chronic hepatitis C using non-invasive biomarkers. Available from: < http://www.has-sante.fr/portail/display.jsp? id=c-476486 > [accessed August 2007].